CareDx Inc. announced the availability of XenoSure donor-derived cell-free DNA (dd-cfDNA) and XenoMap gene-expression profiling for investigational use in xenotransplantation research and post-xenotransplant clinical monitoring. Surgeons from the University of Maryland School of Medicine (UMSOM) recently used XenoSure and XenoMap, two complementary, non-invasive CareDx surveillance solutions, experimentally, for multimodal assessment of organ graft health in the world's first pig-to-human heart xenotransplant. XenoSure is used to detect graft injury and XenoMap to assess immune quiescence.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.57 USD | +0.13% | -8.90% | -36.92% |
Apr. 16 | CareDx Appoints John Hanna as CEO, President | MT |
Apr. 16 | CareDx, Inc Appoints John W. Hanna as Chief Executive Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.92% | 391M | |
-20.07% | 10.67B | |
+43.97% | 3.22B | |
-35.56% | 2.09B | |
-17.21% | 2.04B | |
-28.93% | 1.46B | |
+18.85% | 1B | |
-4.37% | 734M | |
-46.12% | 379M | |
+13.32% | 343M |
- Stock Market
- Equities
- CDNA Stock
- News CareDx, Inc
- CareDx Announces XenoSure and XenoMap